Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 1 4Phase 1/2 3Phase 3 2

Status

Recruiting 2Suspended 1

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 1Other solid neoplasm 1Genitourinary 1Dermatologic 1

Conditions

Prostate Cancer Recurrent 1Multiple Myeloma 1Melanoma 1Carcinoma, Merkel Cell 1Carcinoma, Basal Cell 1

Interventions

pembrolizumab 38Specimen Handling 37Magnetic Resonance Spectroscopy 26Biopsy 26Cyclophosphamide 25Carboplatin 25fludarabine 21Nivolumab 20Gemcitabine 18Dexamethasone 18Paclitaxel 15Rituximab 13Bevacizumab 13Pemetrexed 12Docetaxel 12atezolizumab 11Cisplatin 11Lenalidomide 10Ipilimumab 10Fulvestrant 10venetoclax 9Prednisone 9Oxaliplatin 9olaparib 8fludarabine phosphate 8belantamab mafodotin 8Temozolomide 8Injections 8Fluorouracil 8abemaciclib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Sirolimus × 30 days × Clear all
NCT06876142 2026-05-27

Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma

National Institutes of Health Clinical Center (CC)

Phase 1/2 Suspended
54 enrolled
Plasma cell

Multiple Myeloma

NCT05036226 2026-05-13

COAST

Medical University of South Carolina

Phase 1/2 Recruiting
76 enrolled
GenitourinaryOther solid neoplasm

Prostate Cancer Recurrent

NCT05896839 2026-05-13

Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer

National Cancer Institute (NCI)

Phase 1/2 Recruiting
16 enrolled
Dermatologic

Carcinoma, Basal Cell, Melanoma, Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡